Clinical Significance of miR-146a in Gastric Cancer Cases

Purpose: The profiles of microRNAs change significantly in gastric cancer. MiR-146a is reported to be a tumor suppressor in pancreatic cancer, breast cancer, and prostate cancer. We investigated the clinical significance of miR-146a in gastric cancer, in particular focusing on hypothetical miR-146a target genes, such as epidermal growth factor receptor (EGFR) and interleukin-1 receptor-associated kinase (IRAK1). Experimental Design: We examined miR-146a levels in 90 gastric cancer samples by q-real-time (qRT)–PCR and analyzed the association between miR-146a levels and clinicopathologic factors and prognosis. The regulation of EGFR and IRAK1 by miR-146a was examined with miR-146a–transfected gastric cancer cells. Moreover, we analyzed the association between miR-146a levels and the G/C single nucleotide polymorphism (SNP) within pre-miR-146a seed sequences in 76 gastric cancer samples, using direct sequencing of genomic DNA. Results: In 90 clinical samples of gastric cancer, miR-146a levels in cancer tissues were significantly lower than those in the corresponding noncancerous tissue (P < 0.001). Lower levels of miR-146a were associated with lymph node metastasis and venous invasion (P < 0.05). Moreover, a lower level of miR-146a was an independent prognostic factor for overall survival (P = 0.003). Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells. In addition, G/C SNP within the pre-miR-146a seed sequence significantly reduced miR-146a levels in the GG genotype compared with the CC genotype. Conclusions:MiR-146a contains an SNP, which is associated with mature miR-146a expression. MiR-146a targeting of EGFR and IRAK1 is an independent prognostic factor in gastric cancer cases. Clin Cancer Res; 17(13); 4277–84. ©2011 AACR.

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  Yan Zhou,et al.  A functional polymorphism in Pre-miR-146a is associated with susceptibility to gastric cancer in a Chinese population. , 2012, DNA and cell biology.

[3]  西田 尚弘.  MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab , 2012 .

[4]  Wei Zhang,et al.  A functional polymorphism in Pre‐miR‐146a gene is associated with prostate cancer risk and mature miR‐146a expression in vivo , 2010, The Prostate.

[5]  Zhiwei Wang,et al.  miR-146a suppresses invasion of pancreatic cancer cells. , 2010, Cancer research.

[6]  Kazuhiro Yoshida,et al.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. , 2010, The Lancet. Oncology.

[7]  Xiaohua Li,et al.  Survival prediction of gastric cancer by a seven-microRNA signature , 2009, Gut.

[8]  M. Pistelli,et al.  Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. , 2009, Cancer treatment reviews.

[9]  H. Arkenau.  Gastric cancer in the era of molecularly targeted agents: current drug development strategies , 2009, Journal of Cancer Research and Clinical Oncology.

[10]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[11]  K. Jażdżewski,et al.  Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer , 2009, Proceedings of the National Academy of Sciences.

[12]  Y. Bang,et al.  Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer , 2009, British Journal of Cancer.

[13]  J. Xiang,et al.  Meta‐analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer , 2009, The British journal of surgery.

[14]  Jian-Rong Yang,et al.  A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. , 2008, Carcinogenesis.

[15]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.

[16]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[17]  A. Panani.  Cytogenetic and molecular aspects of gastric cancer: clinical implications. , 2008, Cancer letters.

[18]  Barbara Jarzab,et al.  Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma , 2008, Proceedings of the National Academy of Sciences.

[19]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[20]  Donald C. Chang,et al.  Loss of mir-146a function in hormone-refractory prostate cancer. , 2008, RNA.

[21]  B. Aggarwal,et al.  Epidermal growth factor (EGF) activates nuclear factor-κB through IκBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IκBα , 2007, Oncogene.

[22]  K. Mimori,et al.  Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin‐conjugating enzyme E2C gene expression , 2007, International journal of cancer.

[23]  Peng Jin,et al.  Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. , 2007, Human molecular genetics.

[24]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[25]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[26]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[28]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[29]  H. Lee,et al.  Nuclear Factor-κB Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer , 2005, Clinical Cancer Research.

[30]  M. Tsuneyoshi,et al.  Interleukin 1β Enhances Invasive Ability of Gastric Carcinoma through Nuclear Factor-κB Activation , 2004, Clinical Cancer Research.

[31]  J. McCubrey,et al.  EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). , 2003, International journal of oncology.

[32]  P. Malone,et al.  Prostate , 1995 .

[33]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[34]  B. Aggarwal,et al.  Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. , 2007, Oncogene.

[35]  H. Lee,et al.  Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Tsuneyoshi,et al.  Interleukin 1beta enhances invasive ability of gastric carcinoma through nuclear factor-kappaB activation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. R. Kelley,et al.  Gastric cancer epidemiology and risk factors. , 2003, Journal of clinical epidemiology.

[38]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998 .

[39]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .